LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

LLY

1,000.32

+1.04%↑

JNJ

226.86

+0.95%↑

ABBV

205.07

-1.3%↓

UNH

401.47

+4.08%↑

AZN

184.66

+0.27%↑

Home・Listă Acțiuni・Natera Inc

Natera Inc

Deschisă

SectorSănătate

199 -2.05

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

197.09

Maxim

205.88

Indicatori cheie
By Trading Economics
Venit	-132M -85M
Vânzări	31M 697M
EPS	-0.6
Marjă de profit	-12.214
Angajați	6,135
EBITDA	-38M -73M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+28.37% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.7B 29B
Deschiderea anterioară	201.05
Închiderea anterioară	199

Sentimentul știrilor

By Acuity

39%

61%

115 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

153.79 / N/A Suport & Rezistență

Natera Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2026, 22:50 UTC

Câștiguri

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mai 2026, 22:49 UTC

Câștiguri

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mai 2026, 22:32 UTC

Câștiguri

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mai 2026, 22:57 UTC

Market Talk

Câștiguri

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mai 2026, 22:26 UTC

Câștiguri

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mai 2026, 22:25 UTC

Câștiguri

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mai 2026, 22:25 UTC

Câștiguri

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mai 2026, 22:24 UTC

Câștiguri

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mai 2026, 22:23 UTC

Câștiguri

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mai 2026, 22:23 UTC

Câștiguri

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mai 2026, 22:19 UTC

Câștiguri

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mai 2026, 22:14 UTC

Câștiguri

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mai 2026, 22:14 UTC

Câștiguri

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mai 2026, 22:13 UTC

Câștiguri

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Câștiguri

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Câștiguri

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mai 2026, 22:11 UTC

Câștiguri

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mai 2026, 22:11 UTC

Câștiguri

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mai 2026, 22:10 UTC

Câștiguri

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mai 2026, 22:09 UTC

Câștiguri

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mai 2026, 22:09 UTC

Câștiguri

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mai 2026, 22:08 UTC

Câștiguri

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mai 2026, 22:07 UTC

Câștiguri

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mai 2026, 22:06 UTC

Câștiguri

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mai 2026, 22:06 UTC

Câștiguri

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mai 2026, 22:05 UTC

Câștiguri

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mai 2026, 22:04 UTC

Câștiguri

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparație

Modificare preț

Natera Inc Așteptări

Obiectiv de preț

By TipRanks

28.37% sus

Prognoză pe 12 luni

Medie 262.14 USD 28.37%

Maxim 300 USD

Minim 199.14 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNatera Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 16 analiști care au acordat evaluări ale acțiunilor Natera Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

153.79 / N/ASuport & Rezistență

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

115 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.